PATENT CLAIM ANALYSIS

Application Number: 16179050
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["540", "555000"]

Abstract:
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C  receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C  receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C  receptor.

Claim (Index 50):
A compound of formula I as claimed in any of the preceding claims, selected from\n 8,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinolone; 1,2,3,4-tetrahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclopent[2]en]-6(7H)-one; 8-methyl-8-phenyl-3,4,7,8-tetrahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-6(2H)-one; 8,8-dimethyl-3,4,7,8-tetrahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-6(2H)-one; 1,2,3,4-tetrahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclopentan]-6(7H)-one; 1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclopentane]; 12a-methyl-4,5,6,7,10,11,12,12a-octahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinolin-9(9aH)-one; 8-methyl-8-(trifluoromethyl)-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinolone; 12a-methyl-4,5,6,7,10,11,12,12a-octahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinolin-9(9aH)-one; 12a-methyl-4,5,6,7,9,9a, 10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino-[6,7,1-ij]quinoline; 8-methyl-8-(trifluoromethyl)-3,4,7,8-tetrahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-6(2H)-one; 12a-methyl-4,5,6,7,9,9a, 10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino-[6,7,1-ij]quinoline; 8-methyl-8-phenyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; (R)-5,6,7,9,9a,10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; (S)-5,6,7,9,9a, 10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 9-chloro-8,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 10-chloro-8,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 9-chloro-8,8-dimethyl-3,4,7,8-tetrahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-6(2H)-one; 10-chloro-8,8-dimethyl-3,4,7,8-tetrahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-6(2H)-one; 9-fluoro-8,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 10-fluoro-8,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclohexane]; 1\u2032,2\u2032,3\u2032,4\u2032,6\u2032,7\u2032-hexahydrospiro[cyclobutane-1,8\u2032-]1,4]diazepino[6,7,1-ij]quinoline; 9\u2032-fluoro-1\u2032,2\u2032,3\u2032,4\u2032,6\u2032,7\u2032-hexahydrospiro[cyclobutane-1,8\u2032-[1,4]diazepino[6,7,1-ij]quinoline]; 7,8,8-trimethyl-1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline]; 9-fluoro-1-methyl-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclobutane]; 3-methyl-1\u2032,2\u2032,3\u2032,4\u2032,6\u2032,7\u2032-hexahydrospiro[cyclobutane-1,8\u2032-[1,4]diazepino[6,7,1-ij]quinoline]; 3-benzyl-2\u2032,3\u2032,7\u2032,8\u2032,9\u2032,10\u2032-hexahydro-1H-3\u2032,8\u2032,10a\u2032-triaza-cyclohepta[de]naphthalene; 2,3,5,6,7,8-Hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-Cyclobutyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-Methyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-(Oxetan-3-yl)-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-(Cyclopropylmethyl)-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-(Cyclopentylmethyl)-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; Cyclopropyl(2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxalin-1-yl)methanone; Cyclopentyl(2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxalin-1-yl)methanone; 1-Cyclopropyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-Cyclopentyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-Cyclopropyl-5-methyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 6,6-Dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 5,6,7,9,9a, 10,11,12,13,14-decahydro-4H-azepino[1,2-a][1,4]diazepino[1,7,6-de]quinoxaline; 7-Methyl-5,6,7,9,9 a , 10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 1-Fluoro-7-methyl-5,6,7,9,9 a ,10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 1,2,3,4,6,7-Hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclopropane]; 4-Methyl-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclopropane]; 11-Fluoro-8,8-Dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 10-Methoxy-8,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 4,8,8-Trimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 4-Ethyl-8,8-dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 6,8,8-Trimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 8-ethyl-8-methyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; (R)-8-ethyl-8-methyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; (S)-8-ethyl-8-methyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinoline; 4-Methyl-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclobutane]; 1-Fluoro-5,6,7,9,9a, 10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 1-Bromo-5,6,7,9,9a, 10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 1-Methyl-5,6,7,9,9a, 10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 1-Cyclopropyl-5,6,7,9,9a, 10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 1-Cyclobutyl-5,6,7,9,9a,10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 1-Cyclopentyl-5,6,7,9,9a, 10,11,12-octahydro-4H-[1,4]diazepino[1,7,6-de]pyrrolo[1,2-a]quinoxaline; 8-Methyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-8-ol; 8-Methoxy-8-methyl-2,3,4,67,8-hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline; 2,8-Dimethyl-2,3,4,6,7,8-hexahydro-1H-[1,4]diazepino[6,7,1-ij]quinolin-8-ol; 11-Methyl-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclobutane]; 9-Methyl-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclobutane]; 4,5,6,7,9,9a,9b,10,10a, 11-Decahydrocyclopropa[3,4]pyrrolo[1,2-a][1,4]diazepino[1,7,6-de]quinoxaline; 1-Ethyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-Propyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-Cyclobutyl-5-methyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 5-Methyl-1-(oxetan-3-yl)-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 1-Ethyl-5-methyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 5-Methyl-1-propyl-2,3,5,6,7,8-hexahydro-1H-[1,4]diazepino[1,7,6-de]quinoxaline; 9-Chloro-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclobutane]; 10-Methyl-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclobutane]; 10-Chloro-1,2,3,4,6,7-hexahydrospiro[[1,4]diazepino[6,7,1-ij]quinoline-8,1\u2032-cyclobutane]; and the stereoisomers and pharmaceutically acceptable salts thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.88636
- Patent Class: 540.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13838788', '14657840', '14657916', '14026354', '14868835']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.732012959245135
- 35 USC 102 Novelty (BERT): 0.6113684123513508
- Combined Prediction Score: 0.7199485045557565
- Mean Citation Score: 483.115398
- Max Citation Score: 558.0024
- Similarity Product: 461.51569121246337

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test